Jun 21, 2019 5:30 am EDT Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019 7:00 am EDT Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
May 30, 2019 5:30 am EDT Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 15, 2019 4:05 pm EDT Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
May 7, 2019 5:30 am EDT Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019 5:30 am EDT Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Apr 3, 2019 5:30 am EDT Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
Apr 2, 2019 5:30 am EDT Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Mar 18, 2019 5:30 am EDT Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019